PAGANO MICHELE has a total of 16 patent applications. Its first patent ever was published in 1982. It filed its patents most often in United States, Italy and Canada. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are KINEMED INC, SOCRATECH L L C and TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INST OF GERONTOLOGY.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | Italy | 2 | |
#3 | Canada | 1 | |
#4 | France | 1 | |
#5 | United Kingdom | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology | |
#4 | Civil engineering |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Structural elements | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Pagano Michele | 15 |
#2 | Peschiaroli Angelo | 5 |
#3 | Palumbo Nicola | 4 |
#4 | Mercurio Frank | 3 |
#5 | Lopez-Girona Antonia | 3 |
#6 | Xie Weilin | 3 |
#7 | Skaar Jeffrey R | 2 |
#8 | Bassermann Florian | 2 |
#9 | Dorrello N Valerio | 2 |
#10 | Tanzi Alberto | 1 |
Publication | Filing date | Title |
---|---|---|
US2010016408A1 | Modulating the CDC14B-CDH1-PLK1 axis and methods for sensitizing target cells to apoptosis | |
US2009318535A1 | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis | |
US2009275639A1 | USP47 inhibtors and methods to induce apoptosis | |
US2006088846A1 | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders | |
US4516375A | Framework block or brick consisting of modular elements of formed sheet steel or aluminum and comprising jointing means | |
IT8247691D0 | Metal framework block or brick |